Status:
COMPLETED
Phase II Exploratory Clinical Study of KUX-1151
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Conditions:
Hyperuricemia
Eligibility:
All Genders
20-64 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of multiple oral administration of KUX-1151 in patients with hyperuricemia including gout.
Eligibility Criteria
Inclusion
- Japanese HU patients (Outpatient)
- Patients who meet the following criteria concerning serum uric acid levels at the screening \[1) Gout: \> 7.0 mg/dL, 2) HU with complications: ≥ 8.0 mg/dL, 3) HU without complications: ≥ 9.0 mg/dL\]
Exclusion
- Patients who have any symptom of gouty arthritis within 2 weeks of investigational product administration
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02190786
Last Update
October 19 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tokyo and Other Japanese City, Japan